Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 186

    1.

    Molecular response to aromatase inhibitor treatment in primary breast cancer.

    Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M.

    Breast Cancer Res. 2007;9(3):R37.

    PMID:
    17555561
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.

    Murray J, Young OE, Renshaw L, White S, Williams L, Evans DB, Thomas JS, Dowsett M, Dixon JM.

    Breast Cancer Res Treat. 2009 Apr;114(3):495-501. Epub 2008 Apr 26.

    PMID:
    18438705
    [PubMed - indexed for MEDLINE]
    3.

    Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

    Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

    J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

    PMID:
    18073378
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

    Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

    Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.

    PMID:
    18083065
    [PubMed - indexed for MEDLINE]
    5.

    Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.

    Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM.

    Pharmacogenet Genomics. 2007 Oct;17(10):813-26.

    PMID:
    17885619
    [PubMed - indexed for MEDLINE]
    6.

    Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.

    Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S.

    Mol Cancer Res. 2005 Apr;3(4):203-18.

    PMID:
    15831674
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.

    Miller WR, Stuart M, Sahmoud T, Dixon JM.

    Br J Cancer. 2002 Oct 21;87(9):950-5.

    PMID:
    12434282
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Hormonal therapies for early breast cancer: systematic review and economic evaluation.

    Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

    Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

    PMID:
    17610808
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

    Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.

    BMC Cancer. 2009 Jun 16;9:185.

    PMID:
    19531212
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

    Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC.

    Lancet Oncol. 2005 Jun;6(6):383-91. Erratum in: Lancet Oncol. 2005 Jun;6(6):357.

    PMID:
    15925816
    [PubMed - indexed for MEDLINE]
    11.

    Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

    J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. Epub 2008 Sep 23.

    PMID:
    18812550
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    12.

    Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

    Jahanzeb M.

    Clin Ther. 2007 Aug;29(8):1535-47. Review.

    PMID:
    17919537
    [PubMed - indexed for MEDLINE]
    13.

    Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.

    Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, Veronesi P, D'Alessandro C, Luini A, Dellapasqua S, Viale G, Goldhirsch A, Colleoni M.

    Br J Cancer. 2007 Sep 17;97(6):802-8. Epub 2007 Aug 21.

    PMID:
    17712311
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

    Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA.

    J Clin Oncol. 2011 Jun 10;29(17):2342-9. Epub 2011 May 9.

    PMID:
    21555689
    [PubMed - indexed for MEDLINE]
    16.

    Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

    Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM.

    J Clin Oncol. 2009 Mar 20;27(9):1382-7. Epub 2009 Feb 17.

    PMID:
    19224856
    [PubMed - indexed for MEDLINE]
    17.

    Aromatase inhibitors: cellular and molecular effects.

    Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM.

    J Steroid Biochem Mol Biol. 2005 May;95(1-5):83-9.

    PMID:
    16002280
    [PubMed - indexed for MEDLINE]
    18.

    Primary hormone treatment in postmenopausal women with breast cancer.

    Maciá Escalante S, Pons Sanz V, Rodríguez Lescure A, Ballester Navarro I, Carrato Mena A.

    Clin Transl Oncol. 2006 May;8(5):372-4.

    PMID:
    16760014
    [PubMed - indexed for MEDLINE]
    19.

    Factors predictive of response to hormone therapy in breast cancer.

    Rastelli F, Crispino S.

    Tumori. 2008 May-Jun;94(3):370-83. Review.

    PMID:
    18705406
    [PubMed - indexed for MEDLINE]
    20.

    Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

    J Clin Oncol. 2009 Jun 1;27(16):2630-7. Epub 2009 Apr 20.

    PMID:
    19380449
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk